A healthcare and life sciences IPO market update says biotech dealmaking and listing activity is strengthening in 2026, but investors continue to demand high-quality data and differentiated programs before granting market access. Legal and capital market stakeholders discussed the gap between the current environment and the 2021 peak. The discussion points to crossover rounds for pre-IPO companies and strong clinical evidence as recurring prerequisites. While market activity is described as healthier than in the immediate post-2021 period, the report stresses the underwriting bar remains elevated. The update references Kardigan’s recent U.S. IPO filing as one example of continued listing interest despite strict screening for scientific and management credibility.